Premium Nahrungsergänzungsmittel | artgerecht

Coagulation Activation – Process and Significance

Coagulation activation is the process by which blood clots at the site of a vessel injury to stop bleeding. It is a vital, tightly regulated defence mechanism of the body.

Regular tips about health Regular tips about health

Things worth knowing about "Coagulation Activation"

Coagulation activation is the process by which blood clots at the site of a vessel injury to stop bleeding. It is a vital, tightly regulated defence mechanism of the body.

What is Coagulation Activation?

Coagulation activation refers to the biological process by which blood transforms from a liquid into a solid clot following injury to a blood vessel. This process is part of haemostasis -- the body mechanism for stopping bleeding -- and involves a carefully orchestrated interplay between platelets, coagulation factors, and plasma proteins.

Stages of Coagulation Activation

Primary Haemostasis

Immediately after a vessel is injured, the blood vessel constricts (vasoconstriction) to reduce blood flow. Platelets then adhere to the exposed vessel wall and aggregate to form an initial, unstable platelet plug. This step is facilitated by the von Willebrand factor, a protein that acts as a bridge between platelets and the damaged vessel surface.

Secondary Haemostasis (Coagulation Cascade)

The secondary phase involves the activation of the coagulation cascade, a series of reactions in which clotting factors sequentially activate one another. There are two main pathways:

Extrinsic Pathway (Tissue Factor Pathway): Triggered by tissue factor (TF) released from damaged tissue at the site of injury.
Intrinsic Pathway (Contact Activation): Activated when blood comes into contact with foreign surfaces or altered vessel structures.

Both pathways converge into a common pathway that generates thrombin. Thrombin converts the soluble plasma protein fibrinogen into insoluble fibrin. Fibrin forms a mesh that reinforces the platelet plug into a stable, firm blood clot (thrombus).

Fibrinolysis

Once healing has occurred, the clot is gradually dissolved through a process called fibrinolysis. The enzyme plasmin breaks down the fibrin network, restoring normal blood flow through the vessel.

Causes of Altered Coagulation Activation

Coagulation activation can be either excessive or insufficient:

Excessive coagulation (thrombophilia): Genetic mutations (e.g., Factor V Leiden), prolonged immobility, surgery, certain medications, or systemic illnesses can increase clotting activity and raise the risk of thrombosis.
Insufficient coagulation (haemophilia, clotting deficiencies): Absent or reduced clotting factors (e.g., in haemophilia A or B) or low platelet counts can lead to an increased tendency to bleed.

Clinical Relevance

Disturbances in coagulation activation can be life-threatening. Key conditions include:

Deep vein thrombosis (DVT)
Pulmonary embolism
Heart attack and stroke (caused by arterial thrombus formation)
Disseminated intravascular coagulation (DIC): a severe disorder in which the entire clotting system is activated uncontrollably throughout the body
Haemophilia and other inherited bleeding disorders

Diagnosis

Several laboratory tests are available to assess coagulation activation:

Prothrombin time (PT) / INR: Evaluates the extrinsic coagulation pathway
aPTT (activated partial thromboplastin time): Evaluates the intrinsic coagulation pathway
Platelet count: Assesses the number of platelets available for clot formation
D-dimers: Elevated levels indicate increased clotting activity and fibrinolysis
Individual clotting factor assays: e.g., Factor VIII in suspected haemophilia A

Treatment

Treatment depends on the type of coagulation disorder:

Anticoagulants (e.g., heparin, warfarin, direct oral anticoagulants such as rivaroxaban) inhibit coagulation activation and are used to prevent or treat thrombosis.
Thrombolytics (e.g., alteplase) dissolve existing blood clots and are used in acute emergencies such as pulmonary embolism or stroke.
Clotting factor concentrates are administered in cases of inherited clotting deficiencies such as haemophilia.
Platelet transfusions may be required in cases of severe thrombocytopenia (low platelet count).

References

Pschyrembel Clinical Dictionary. 268th Edition. De Gruyter, Berlin 2020.
Levi M, van der Poll T. Coagulation and sepsis. Thrombosis Research. 2017;149:38-44. PubMed PMID: 28040521.
World Health Organization (WHO). Inherited bleeding disorders. Available at: https://www.who.int (accessed 2024).

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.